Close Menu

Iverson Genetics

This article has been updated from an earlier version with additional information about the design and size of the WARFARIN trial. Additionally, Iverson has further clarified the difference between its study and the COAG trial.

NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics said today it has received global exclusive rights from Johns Hopkins University School of Medicine to commercialize a molecular diagnostic test.

Columbia University of New York has received US Patent No. 8,133,492, "Pneumococcus polysaccharide-related vaccines." Nitrocellulose-based or hydrogel-based microarrays and methods of making them are claimed.

NEW YORK (GenomeWeb News) – Iverson Genetic Diagnostics announced a collaboration with Vanderbilt University aimed at molecular diagnostics to assess breast cancer risk in menopausal women.

Iverson Genetic Diagnostics said this week that the Franciscan Health System in Tacoma, Wash., has begun enrolling patients for the WARFARIN (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) study that the company is leading in an effor

This story has been updated from a version published Aug. 15 to reflect the fact that Iverson Genetics has not yet selected a testing partner for the WARFARIN trial.

While past studies that have attempted to gauge the clinical utility of warfarin PGx testing have been hampered by slow test turnaround times, Iverson is promising to provide genetic test results within 24 hours.

In Brief This Week is a Friday column containing news items that our readers may have missed during the week.

GenMark said that its PCR-based eSensor warfarin sensitivity test panel and XT-8 platform have been selected for use in a clinical trial to assess the impact of genotype on the occurrence of adverse events during warfarin drug therapy.

The CMS approval "is for a clinical study under 'coverage with evidence development' and will cover pharmacogenetic testing of CYP2C9 or VKORC1 alleles to predict warfarin responsiveness," Iverson Genetics said in a statement.

Pages

Two COVID-19 vaccine developers have released their trial protocols to build public trust, the New York Times reports.

A new analysis finds the rapid COVID-19 test from DnaNudge to be highly accurate, Reuters reports.

In Science this week: global citizens' assembly on genome-editing technologies proposed, epigenetic markers predict metformin response, and more.

According to the Verge, many US states are not including positive results from rapid COVID-19 testing in their case numbers.